| pubmed-article:2588999 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2588999 | lifeskim:mentions | umls-concept:C0024591 | lld:lifeskim |
| pubmed-article:2588999 | lifeskim:mentions | umls-concept:C0027849 | lld:lifeskim |
| pubmed-article:2588999 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:2588999 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:2588999 | pubmed:dateCreated | 1990-1-5 | lld:pubmed |
| pubmed-article:2588999 | pubmed:abstractText | The neuroleptic malignant syndrome (NMS) is an uncommon but dangerous complication of treatment with neuroleptic drugs. A primary defect in skeletal muscle has been suggested in view of similarities in the clinical presentations of NMS and anaesthetic-induced malignant hyperthermia (MH). The in vitro halothane-caffeine contracture tests are the most reliable method of identifying individuals susceptible to MH. The aim of this study was to define if a relationship exists between NMS and MH susceptibility. Hence, the in vitro halothane and caffeine contracture tests were performed on muscle tissue obtained from eight NMS, ten MH-susceptible and ten control patients. The results, which are expressed in accordance with the criteria of the European MH Group, defined the eight NMS subjects as MH non-susceptible. The response to halothane and caffeine exposure of skeletal muscle from NMS and control subjects was the same and significantly different from that of muscle from patients susceptible to MH. Furthermore, muscle from subjects in NMS and control group responded similarly to increasing concentrations of chlorpromazine. These results do not point towards an association between NMS and MH. | lld:pubmed |
| pubmed-article:2588999 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2588999 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2588999 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2588999 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2588999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2588999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2588999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2588999 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2588999 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:2588999 | pubmed:issn | 0001-5172 | lld:pubmed |
| pubmed-article:2588999 | pubmed:author | pubmed-author:HaudecoeurGG | lld:pubmed |
| pubmed-article:2588999 | pubmed:author | pubmed-author:DupuisB ABA | lld:pubmed |
| pubmed-article:2588999 | pubmed:author | pubmed-author:AdamantidisM... | lld:pubmed |
| pubmed-article:2588999 | pubmed:author | pubmed-author:AdnetP JPJ | lld:pubmed |
| pubmed-article:2588999 | pubmed:author | pubmed-author:Krivosic-Horb... | lld:pubmed |
| pubmed-article:2588999 | pubmed:author | pubmed-author:SaulnierFF | lld:pubmed |
| pubmed-article:2588999 | pubmed:author | pubmed-author:Adnet-BonteC... | lld:pubmed |
| pubmed-article:2588999 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2588999 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:2588999 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2588999 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2588999 | pubmed:pagination | 676-80 | lld:pubmed |
| pubmed-article:2588999 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:meshHeading | pubmed-meshheading:2588999-... | lld:pubmed |
| pubmed-article:2588999 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2588999 | pubmed:articleTitle | The association between the neuroleptic malignant syndrome and malignant hyperthermia. | lld:pubmed |
| pubmed-article:2588999 | pubmed:affiliation | Department of Anesthesiology, Faculty of Medicine, University of Lille, France. | lld:pubmed |
| pubmed-article:2588999 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2588999 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2588999 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2588999 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2588999 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2588999 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2588999 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2588999 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2588999 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2588999 | lld:pubmed |
